Luigi Naldini
Founder chez GENENTA SCIENCE S.P.A.
Fortune : 5 M $ au 31/03/2024
Profil
Luigi Naldini is the founder of Magenta Therapeutics, Inc. (2015), GeneSpire Srl (2020), Epsilen Bio Srl (2019), and Genenta Science SpA (2014).
At Genenta Science SpA, he holds the title of Chairman-Executive Scientific Board.
Dr. Naldini's current jobs include Director at San Raffaele-Telethon Institute for Gene Therapy, Director at American Society of Gene & Cell Therapy, and Professor at Università Vita-Salute San Raffaele.
He previously held the position of President at European Society of Gene & Cell Therapy.
Dr. Naldini received his doctorate degrees from the University of Turin and Università degli Studi di Roma Tor Vergata.
Dr. Naldini is also the founder of Chroma Medicine, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GENENTA SCIENCE SPA
7,61% | 19/04/2023 | 1 386 145 ( 7,61% ) | 5 M $ | 31/03/2024 |
Postes actifs de Luigi Naldini
| Sociétés | Poste | Début |
|---|---|---|
| GENENTA SCIENCE S.P.A. | Founder | 24/07/2014 |
| San Raffaele-Telethon Institute for Gene Therapy | Director/Board Member | - |
| Università Vita-Salute San Raffaele | Corporate Officer/Principal | - |
American Society of Gene & Cell Therapy
 American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Director/Board Member | - |
Anciens postes connus de Luigi Naldini
| Sociétés | Poste | Fin |
|---|---|---|
Chroma Medicine, Inc.
 Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Founder | - |
| European Society of Gene & Cell Therapy | President | - |
GeneSpire Srl
 GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | Founder | - |
Epsilen Bio Srl
 Epsilen Bio Srl Pharmaceuticals: MajorHealth Technology Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy. | Founder | - |
| MAGENTA THERAPEUTICS | Founder | - |
Formation de Luigi Naldini
| University of Turin | Doctorate Degree |
| Università degli Studi di Roma Tor Vergata | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GENENTA SCIENCE S.P.A. | Health Technology |
| Entreprise privées | 7 |
|---|---|
| European Society of Gene & Cell Therapy | |
| San Raffaele-Telethon Institute for Gene Therapy | |
American Society of Gene & Cell Therapy
American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Commercial Services |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
GeneSpire Srl
GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | Health Technology |
Epsilen Bio Srl
Epsilen Bio Srl Pharmaceuticals: MajorHealth Technology Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy. | Health Technology |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Health Technology |
